RAD-140 + LGD-4033 Research Stack in Canada
This research stack contains RAD-140 (Testolone) and LGD-4033 (Ligandrol) as 2 separate, labelled liquid research solutions. The compounds are not premixed. The bundle is intended for laboratory identification, comparative documentation, and controlled research inventory; it is not a dietary supplement, medication, or product for human or veterinary use.
Stack specifications
| Compound | Listed concentration | Volume | Total listed compound | Documentation |
|---|---|---|---|---|
| RAD-140 (Testolone) | 10 mg/mL | 30 mL | 300 mg | Applicable material-lot COA on request |
| LGD-4033 (Ligandrol) | 10 mg/mL | 30 mL | 300 mg | Applicable material-lot COA on request |
How this research bundle is organized
Every included compound is a selective androgen receptor modulator, but each remains a distinct research material with its own identity, concentration, literature, and documentation.
This two-compound listing keeps comparison limited to RAD-140 and LGD-4033. Each remains in its own container, making identity and documentation review more direct than in a three-compound catalogue bundle.
Separate containers preserve product identity and make it possible to review the label, concentration, storage information, and available Certificate of Analysis for each material independently. The stack name describes a catalogue bundle only; it does not claim synergy, compatibility, safety, or a combined effect.
Research context for the included compounds
RAD-140 (Testolone)
RAD-140 has been investigated as a nonsteroidal androgen-receptor ligand in preclinical development and in an open-label first-in-human oncology dose-escalation study. The published human study involved 22 postmenopausal patients with metastatic breast cancer. It was not a consumer-safety study, and liver-test elevations were common in that monitored population.
LGD-4033 (Ligandrol)
LGD-4033 has published human pharmacokinetic data from a randomized, placebo-controlled 21-day study involving 76 healthy men. The study measured pharmacokinetics and multiple biomarkers and reported dose-related changes in several hormone and lipid measures. A short exploratory trial does not establish long-term safety or product approval.
The studies summarized above used specific experimental designs and populations. They should not be generalized into personal-use outcomes or read as evidence that combining these materials is safe or effective.
Why separate bottles and specifications matter
Each included solution has its own concentration and total listed amount. Keeping the compounds separate supports clearer inventory records, analytical sampling, and documentation review. It also avoids representing the products as a new premixed formulation with an untested combined concentration.
Researchers should record each compound separately and use the label and applicable documentation associated with that individual product. The presence of multiple products in one order does not create evidence about interactions between them.
Purity, HPLC documentation, and material-lot COAs
The listed purity specification for each incoming compound material is ≥98%, with third-party HPLC documentation maintained for the applicable material lot. COA documentation relates to the applicable incoming material batches; its references are not expected to match separate numbers on individual finished bottles.
To request available documentation, email [email protected] with the product names or order number. Review Testing & COA Documentation for guidance on identity, purity, analytical method, dates, and material-lot references.
Research-use boundaries and handling
Every product in this bundle is sold strictly for laboratory and research purposes. The products are not intended for human consumption, therapeutic use, bodybuilding use, athletic performance use, veterinary use, or the diagnosis, treatment, cure, or prevention of disease.
Keep every container sealed and follow its own label or accompanying storage information. Do not assume that different compounds or carrier systems have identical handling requirements. Contact support for product-specific documentation questions.
Frequently asked questions
What is included in this research stack?
The bundle includes one 30 mL bottle of RAD-140 (Testolone) at 10 mg/mL and one 30 mL bottle of LGD-4033 (Ligandrol) at 10 mg/mL. All containers are separately labelled.
Are the compounds premixed?
No. Each compound is supplied in its own bottle so identity, concentration, storage, sampling, and documentation can be managed separately.
Are all included compounds SARMs?
Every included compound is a selective androgen receptor modulator, but each remains a distinct research material with its own identity, concentration, literature, and documentation.
Can I request the applicable COAs?
Yes, where applicable. COAs relate to the incoming material lot for each compound. COA references relate to the tested incoming material batch rather than individual finished bottles.
Does this page provide a dosage, cycle, or combination protocol?
No. This page describes product identity, format, documentation, and published research context only. It does not provide administration, dosage, cycle, stacking, bodybuilding, or medical instructions.
Where can I review broader research information?
Use the Research Library, the Complete SARMs Guide, and the FAQ.
J. (verified owner) –
Order confirmation came instantly, and delivery took three days. (Edited by moderator to remove personal-use claims.)
Paul (verified owner) –
The package arrived with a dent, but the bottles were fine. (Edited by moderator to remove personal-use claims.)